ZBTB16 and prostate cancer: A recent study explored, in detail, PLZF expression in prostate cancers showing that PLZF mRNA expression was lower in tumors with PLZF deletions; there was a strong, positive association between intratumoral AR signaling and PLZF expression; PLZF expression was lower in tumors with PTEN loss; low PLZF expression was associated with higher MAPK signaling; and patients with clearly low PLZF expression were the most likely to develop lethal prostate cancer, independently of clinicopathologic features [310].